The COVID-19 vaccine confers protection against the development of post-COVID-19 conditions, particularly during the Delta and Omicron eras.

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

The following first ran on CounterPunch at the height of the COVID pandemic in January of 2022. Are anti-vaccine ...

It can happen even after a mild case and at any age, although rates have declined since the pandemic’s early years. Studies show vaccination can lower the risk. It also is not clear what causes long ...

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

The support is designed to speed development of well-matched H5N1 vaccines and pave the way for vaccines against other ...

In this study, the authors estimated that Paxlovid reduced the risk of hospitalization by 39% (95% confidence interval [CI], ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

The short explanation is that demand for Moderna's COVID-19 vaccine has plunged since the end of the pandemic. Moderna still has quite a bit of cash and some promising candidates. The main reason ...

Since then, though, Moderna has traveled along a rough path. Demand for the coronavirus vaccine has dropped significantly, and even the company's second approved product -- respiratory syncytial ...

The AstraZeneca and Johnson & Johnson vaccines were linked to a rare, but serious, blood clot in the brain and their use was restricted to certain groups. The Pfizer and Moderna jabs, meanwhile ...